![]()
Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for authoritative information. This article is intended solely for the introduction of medications related to medical health and does not recommend treatment plans (if mentioned); such content does not represent the platform’s position.Authorization is required for any article reprint.
On July 6, Guangzhou Pharmaceutical Holdings Limited announced publicly thatLiu Jian Appointed as Strategic Scientist at Guangzhou Pharmaceutical Holdings LimitedPrior to joining Guangzhou Pharmaceutical Holdings Limited, Mr. Liu Jian served as a member of the Global Executive Committee, Chief Executive Officer of the Innovation Center, and Chairman of Biopharmaceuticals at BeOne. Previously, Mr. Liu spent many years engaged in new drug development, investment and financing management, and pharmaceutical distribution at Pfizer, Sanofi, AstraZeneca, Novartis, and Johnson & Johnson Pharmaceuticals, establishing himself as a seasoned expert and executive in the innovative drug industry.
Guangzhou Pharmaceutical Holdings Limited is a leading pharmaceutical manufacturing enterprise in China and has been listed on the Fortune Global 500 for five consecutive years. Baiyunshan (SH600332, share price RMB 21.05, market capitalization RMB 34.223 billion) is the core listed subsidiary of Guangzhou Pharmaceutical Holdings Limited. In 2025, it ranked fourth among all A-share listed pharmaceutical companies and first among traditional Chinese medicine enterprises, with annual revenue of RMB 77.656 billion. However, as China’s pharmaceutical industry undergoes transformation, the era of coasting to success by relying on time-honored brands, legacy products, and traditional distribution channels has come to an end. Innovation has become a common challenge facing all established leading pharmaceutical companies.Liu Jian has extensive experience in the research and development of biopharmaceuticals, industrialization, and multinational corporate management.Liu Jian joined BeOne in 2018, serving for nearly eight years. During his tenure, he concurrently held three core positions: Member of the Global Executive Committee of BeOne, Chairman of Biopharmaceuticals, and Chief Executive Officer of Bio-Island Innovation Center.Mr. Liu Jian led the innovative drug incubation business at BeOne’s Innovation Center, transforming cutting-edge scientific concepts into high-quality commercial assets. He also spearheaded the establishment of BeOne’s biologics manufacturing base in Guangzhou. With extensive experience in new drug development, investment and financing management, and pharmaceutical distribution at Pfizer, Sanofi, AstraZeneca, Novartis, and Johnson & Johnson Pharmaceuticals, Mr. Liu is a seasoned expert and executive in the innovative pharmaceutical industry.In his new role as Strategic Scientist at Guangzhou Pharmaceutical Holdings Limited, Dr. Liu Jian will become a core member of the company’s strategic development team for innovation-driven transformation. Leveraging his profound insights into the global biopharmaceutical landscape and extensive industry experience, he will spearhead initiatives in tackling major diseases, building an innovative drug pipeline, and facilitating the commercialization of scientific and technological achievements.
Since last year, Guangzhou Pharmaceutical Holdings Limited has intensified its efforts to build a high-caliber talent pool in the biopharmaceutical sector. To date, it has engaged more than 40 leading domestic and international experts, including Academicians Rao Zihe and Ma Jun, to establish the Group’s top-level scientific and technological innovation think tank. The company currently employs over 400 experts with senior professional titles, more than 135 individuals holding doctoral or postdoctoral qualifications, and over 20 professionals classified as high-level talents. These experts continue to solidify the foundation for industrial innovation.Guangzhou Pharmaceutical Holdings Limited (GPHL) further stated that it has currently recruited or is in the process of recruiting nearly 20 high-level leading talents under its “5+5” initiative, including Dr. Liu Jian. Among them are many senior R&D professionals and business development (BD) experts specializing in innovative drugs, with prior experience at top global pharmaceutical companies such as Johnson & Johnson, Eli Lilly, Merck & Co., Novartis, and AstraZeneca. Moving forward, GPHL will continue to attract high-caliber talent with expertise in biomedical R&D and industrialization, thereby accelerating its strategic layout in the innovative drug development sector and sustaining its core market competitiveness.At the 2026 annual work conference held in January, the new management team of Guangzhou Pharmaceutical Holdings Limited proposed the strategic goal of “building another GPHL.” In March, the inaugural investment promotion conference was launched in Wuhan. Innovative drugs serve as a powerful lever to achieve this objective. Guangzhou Pharmaceutical Holdings Limited stated that,Currently, Guangzhou Pharmaceutical Holdings Limited is accelerating its strategic layout in cutting-edge fields such as cell and gene therapy, nucleic acid drugs, radiopharmaceuticals, monoclonal/bispecific/multispecific antibodies, and antibody-drug conjugates (ADCs).Currently, the Group has nearly 200 R&D projects in progress, extensively covering major disease areas such as malignant tumors, chronic disease management, respiratory diseases, immune system disorders, and men's health medications.Field.Furthermore, Guangzhou Pharmaceutical Holdings Limited is spearheading the establishment of the Guangdong-Hong Kong-Macao Greater Bay Area Center for Regional Technology Transfer and Commercialization in Biomedicine for Universities Nationwide.Established multiple sub-platforms for CGT therapeutics, including stem cells, immune cells, viruses, plasmids, and mRNA, as well as peptide and antibody drugs., providing end-to-end translational R&D services from proof of concept and animal studies to pilot-scale production,Advancing the Implementation of the First Batch of 33 CGT Project Collaborations。In 2026, Guangzhou Pharmaceutical Holdings Limited announced that during the period from 2026 to 2030, it plans to invest RMB 10–15 billion in research and development and RMB 20–30 billion in industrial investment and mergers and acquisitions, accelerating its innovation-driven transformation at full speed.However, the development of innovative drugs carries high risks, often described within the industry as a “nine-to-one mortality” endeavor. Guangzhou Pharmaceutical Holdings Limited has previously stated that it respects the objective realities of pharmaceutical innovation—namely, its high risk and long development cycles—and continues to improve fault-tolerance and correction mechanisms for innovative projects, thereby encouraging innovation and embracing failure.Notably, on July 3, Xiangxue Pharmaceutical (stock abbreviation: *ST Xiangxue) announced that Guangzhou Guangyao Capital Co., Ltd. (hereinafter referred to as “Guangyao Capital”) had been selected as the restructuring investor for the company. Guangyao Capital is wholly owned by Guangzhou Pharmaceutical Holdings Limited (hereinafter referred to as “Guangyao Group”). If Xiangxue Pharmaceutical successfully enters the restructuring process, Guangyao Group is expected to become its new controlling shareholder.Xiangxue Pharmaceutical is the only company globally to have simultaneously deployed both TCR-T and TCR drug technologies, two cutting-edge fields, and has established six major innovation platforms, including the National Engineering Research Center for Traditional Chinese Medicine Decoction Pieces.its independently developed TAEST16001 injection, it is the first TCR-T cell therapy product approved for clinical trials in China. In May 2026, it officially entered the confirmatory clinical trial phase. Current clinical data show a treatment efficacy rate of 40%–50%, with production costs amounting to only half those of imported products of the same type. It has also been included in the Breakthrough Therapy Designation list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). Based on the current R&D progress, the product is expected to receive formal marketing approval around 2028, at which point it will become the first TCR-T cell therapy product approved in China and the second globally.This cutting-edge cell therapy pipeline naturally synergizes with the in vitro diagnostic technologies of Da An Gene, recently acquired by Guangzhou Pharmaceutical Holdings Limited (GPHL), directly establishing a complete industrial closed loop of “precision diagnostic identification – cell therapy intervention.” This aligns closely with GPHL’s long-term strategic layout in its two core growth sectors: biological innovative drugs and diagnostic instruments.
Reference: Company Announcements
Scan the QR code to join the groupMastering CAR-T Therapy, Stem Cell Therapy, and GeneTherapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
